SCHEMBL2203104

SCHEMBL2203104

CC(C)(CCC(=O)O)CC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.65
CPT2 P23786 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
KDM4E B2RXH2 1/20 0.52
HMGCR P04035 1/20 0.48
CHRM1 P11229 1/20 0.48
TBXA2R P21731 1/20 0.48
ADRA1A P35348 1/20 0.48
HIF1A Q16665 3/20 0.46
TSHR P16473 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
NAALAD2 Q9Y3Q0 1/20 0.45
BHMT Q93088 3/20 0.43
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
ESR1 P03372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15074709 0.88 FFAR1 (0.52) FFAR1CPT2TDP1KDM4EHMGCR
SCHEMBL2999282 0.86 FFAR1 (0.75) FFAR1CPT2TDP1KDM4EHMGCR
SCHEMBL11529406 0.86 NAALAD2 (0.50) FFAR1CPT2TDP1KDM4EHMGCR
SCHEMBL5302072 0.85 TDP1 (0.74) FFAR1CPT2TDP1KDM4EHMGCR
SCHEMBL3280409 0.85 FFAR1 (0.60) FFAR1CPT2TDP1KDM4EHMGCR
Hydrochloric Acid SCHEMBL31279551 0.83 NAALAD2 (0.48) FFAR1CPT2TDP1KDM4EHMGCR
Sebacic Acid SCHEMBL28078194 0.83 TDP1 (0.71) FFAR1CPT2TDP1KDM4EADRA1A
SCHEMBL12056017 0.82 FFAR1 (0.62) FFAR1CPT2TDP1KDM4EHMGCR
SCHEMBL14360742 0.81 TDP1 (0.83) FFAR1CPT2TDP1KDM4EADRA1A
SCHEMBL2496692 0.81 TDP1 (0.83) FFAR1CPT2TDP1KDM4EADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150259311-A1 METHOD OF PRODUCING LACTONE FROM HYDROXYCARBOXYLIC ACID OR DICARBOXYLIC ACID IN AQUEOUS SOLUTION SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-09-17 US claimed
US-20130204015-A1 PROCESS FOR PREPARING A LACTONE RHODIA OPERATIONS (FR) 2013-08-08 US claimed
CN-102834172-A Method for preparing a lactone RHODIA OPERATIONS 2012-12-19 CN claimed
CN-102702940-A Floating coating for automobile TIANCHANG JULONG TRAVEL PAINT CO LTD 2012-10-03 CN claimed
US-5856581-A DECARBOXYLATING/CYCLIZING A DICARBOXYLIC ACID, IN LIQUID PHASE, IN THE PRESENCE OF A CATALYTICALLY EFFECTIVE AMOUNT OF A METAL OR COMPOUND COMPOUND THEREOF SELECTED FROM AMONG BORON, ALUMINUM, GALLIUM, INDIUM, THALLIUM, TIN, ANTIMONY, RHONE-POULENC CHIMIE (FR) 1999-01-05 US claimed
EP-0626364-B1 Process for the preparation of a cyclic ketone RHONE POULENC CHIMIE (FR) 1998-04-08 EP claimed
EP-0626363-B1 Process for the préparation of a cyclic ketone RHONE POULENC CHIMIE (FR) 1998-03-04 EP claimed
US-5600013-A CATALYTIC CARBOXYLATION AND CYCLIZATION OF DICARBOXYLIC ACIDS RHONE-POULENC CHIMIE (FR) 1997-02-04 US claimed
EP-4514769-B1 MUSKY ODORANT FIRMENICH & CIE (CH) 2026-04-15 EP disclosed
US-20250263629-A1 MUSKY ODORANT FIRMENICH SA (CH) 2025-08-21 US disclosed
EP-4514769-A1 MUSKY ODORANT Firmenich SA (CH) 2025-03-05 EP disclosed
CN-119095821-A Musk odorants 弗门尼舍有限公司 2024-12-06 CN disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
WO-2006035061-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-04-06 WO disclosed
EP-1608631-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA SCIOS INC. (US) 2005-12-28 EP disclosed
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta SCIOS, INC. 2005-01-06 US disclosed
WO-2004087056-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ SCIOS INC. (US) 2004-10-14 WO disclosed
US-5856581-A DECARBOXYLATING/CYCLIZING A DICARBOXYLIC ACID, IN LIQUID PHASE, IN THE PRESENCE OF A CATALYTICALLY EFFECTIVE AMOUNT OF A METAL OR COMPOUND COMPOUND THEREOF SELECTED FROM AMONG BORON, ALUMINUM, GALLIUM, INDIUM, THALLIUM, TIN, ANTIMONY, RHONE-POULENC CHIMIE (FR) 1999-01-05 US disclosed
US-5600013-A CATALYTIC CARBOXYLATION AND CYCLIZATION OF DICARBOXYLIC ACIDS RHONE-POULENC CHIMIE (FR) 1997-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130204015-A1 PROCESS FOR PREPARING A LACTONE HSD17B7, HSD17B3, RPS3 FFAR1 3056/4885CPT2 1757/4885TDP1 4802/4885
US-20250263629-A1 MUSKY ODORANT TRPA1, MSMO1, MSH2 FFAR1 250/4885CPT2 635/4885TDP1 2647/4885
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta TYMP, TYMS, TGFBR1 FFAR1 3969/4885CPT2 4310/4885TDP1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.